HK Stock Market Move | GENSCRIPT BIO (01548) fell by nearly 3%, expecting a loss of over 500 million dollars last year.

GENSCRIPT BIO (01548) fell nearly 3%, falling 2.95% as of the time of publication, to HK$11.53, with a turnover of HK$46.6423 million. In terms of news, GENSCRIPT BIO announced that it is expected to incur a loss of approximately USD 506 million to USD 586 million for the fiscal year ending December 31, 2025, compared to a profit of approximately USD 2.9 billion in the previous period. The expected shift from profit to loss is mainly due to the high base effect generated in the previous period, including approximately USD 3.2 billion in one-time unrealized gains resulting from the dissolution of mergers. For the year, it is estimated that the adjusted net profit from continuing operations will be approximately USD 207 million to USD 242 million, representing an increase of 246.5% to 304.3% from the same period last year. Morgan Stanley noted that after GENSCRIPT BIO issued a profit warning, it reduced its profit forecast for the years 2026 to 2030 by 1% to 13%, and correspondingly lowered the target price from HK$18.30 to HK$16.50, maintaining a "buy" rating.